Shattuck Labs (STTK) Company Report

Shattuck Labs (STTK) is developing a novel DR3 (TL1A receptor) blocking antibody, differentiating its approach from other TL1A therapies that target the ligand.
The company is currently halfway through a Phase 1 study in healthy volunteers, with preclinical and non-human primate studies showing no evidence of receptor agonism.
This receptor-blocking approach is anticipated to offer a superior immunogenicity profile (lower anti-drug antibody formation) and potentially improved efficacy due to the stable expression of the receptor on lymphocytes.
Shattuck Labs is also developing a half-life extended version of its lead antibody and plans for non-IBD Phase 2 studies, including exploring a potential DR3 bispecific with IL-23.

6 days ago

Transcript

Shattuck Labs Details Novel TL1A Receptor-Blocking Antibody Strategy

STTK

New Projects/Investments

Shattuck Labs is developing a DR3 (TL1A receptor) blocking antibody, distinguishing its approach from other TL1A programs that target the ligand.
This receptor-blocking strategy aims to provide a superior immunogenicity profile by preventing the formation of immune complexes, which are a known cause of anti-drug antibodies (ADA) in ligand-targeted therapies.
The company's lead DR3 blocking antibody is halfway through a Phase 1 healthy volunteer study, with preclinical data showing no evidence of receptor agonism and early indicators supporting a differentiated immunogenicity profile.
Shattuck Labs anticipates superior efficacy by targeting the consistently expressed receptor on lymphocytes, offering a stable target compared to the pulsatile expression of the TL1A ligand.
Future development plans include a half-life extended variant of their lead asset, a non-IBD Phase 2 study, and the exploration of DR3-directed bispecifics.

6 days ago

Transcript

Shattuck Labs Provides Update on DR3 Blocking Antibody SL-325 Development

STTK

New Projects/Investments

Guidance Update

Shattuck Labs is developing SL-325, a DR3 blocking antibody that targets the TL1A/DR3 axis for inflammatory diseases, with the belief that it offers advantages over TL1A blocking antibodies by potentially avoiding immunogenicity and providing more durable inhibition.
Preclinical studies for SL-325 demonstrated high affinity, specificity, and a favorable safety profile, showing no adverse events in monkey toxicology studies and achieving full receptor occupancy at low doses.
The company is currently conducting a Phase I study in healthy volunteers for SL-325, with data anticipated in the first half of 2026 and Phase II trials expected to commence in 2026.
Shattuck Labs is funded through its Phase II trials with cash into 2029, a result of a recent PIPE financing.

8 days ago

Transcript

Shattuck Labs Updates on SL325 Clinical Development and Funding

STTK

New Projects/Investments

Guidance Update

Shattuck Labs (STTK) is developing SL325, a DR3 blocking antibody, for inflammatory bowel diseases, which they believe offers advantages over TL1A blocking antibodies by potentially avoiding immunogenicity and providing more durable inhibition of the TL1A DR3 axis.
The Phase 1 study for SL325 is ongoing in healthy volunteers, with data expected to be shared in the first half of 2026.
The company is funded through planned Phase 2 trials, with cash projected into 2029, and expects to begin Phase 2 trials in 2026.

8 days ago

Transcript

Shattuck Labs Reports Q3 2025 Financial Results and SL-325 Clinical Progress

STTK

Earnings

Guidance Update

New Projects/Investments

Shattuck Labs reported a net loss of $10.1 million, or $0.14 per basic and diluted share, for the third quarter of 2025, an improvement from a net loss of $16.6 million, or $0.33 per share, in the prior year period.
As of September 30, 2025, cash and cash equivalents and short-term investments were $86.1 million. The company expects this, combined with the full exercise of common stock warrants, to fund operations into 2029.
The first participants were dosed in a Phase 1 clinical trial of SL-325 in healthy volunteers during the third quarter of 2025, marking its entry into clinical development.
Research and Development (R&D) expenses for Q3 2025 were $7.6 million, down from $16.3 million in Q3 2024.

Nov 6, 2025, 9:32 PM

8-K

Shattuck Labs Reports Q3 2025 Financial Results and SL-325 Clinical Progress

STTK

Earnings

Guidance Update

New Projects/Investments

Shattuck Labs reported a net loss of $10.1 million for the third quarter ended September 30, 2025, and held $86.1 million in cash and cash equivalents and short-term investments as of that date.
The company initiated a Phase 1 clinical trial for its lead product candidate, SL-325, in the third quarter of 2025, with enrollment completion and initial results anticipated by the second quarter of 2026.
A private placement of up to $103 million was closed in August 2025, which is expected to fund operations into 2029, assuming full exercise of common stock warrants.

Nov 6, 2025, 9:30 PM

Press Release

Shattuck Laboratories Discusses DR3 Blocking Antibody Development

STTK

Product Launch

New Projects/Investments

Guidance Update

Shattuck Laboratories (STTK) is developing SL325, a first-in-clinic and potentially first-in-class death receptor three (DR3) blocking antibody, for inflammatory bowel disease (IBD) and other autoimmune diseases.
The company emphasizes that targeting DR3 directly, rather than its ligand TL1A, offers potential advantages including superior efficacy due to DR3's stable and broader expression, and reduced immunogenicity by avoiding immune complex formation.
Shattuck Laboratories expects its Phase 1 study for SL325 to be completed in the first half of 2026, after which it plans to immediately advance into multiple placebo-controlled Phase 2 trials, including one for IBD.
The development of SL325 addresses the significant challenge of avoiding residual agonism, positioning Shattuck Laboratories as the first to develop a pure DR3 antagonist.

Oct 8, 2025, 2:00 PM

Transcript

Shattuck Labs Closes Private Placement and Announces Board Changes

STTK

Board Change

New Projects/Investments

Shattuck Labs, Inc. closed a private placement of up to $103 million, with proceeds expected to fund operations into 2029 assuming full exercise of common stock warrants.
The financing is anticipated to advance SL-325 through multiple Phase 2 clinical trials, including for Inflammatory Bowel Disease (IBD).
The company appointed Daniel Baker, M.D., and Mona Ashiya, Ph.D., to its Board of Directors, while Tyler Brous, Carrie Brownstein, M.D., Michael Lee, and Kate Sasser, Ph.D., resigned.